Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 12, 2010, Pages 1757-1764

  Shedden, Arthur ^a   Adamsons, Ingrid A ^a   Getson, Albert J ^a   Laurence, Jean K ^a   Lines, Christopher R ^a   Hewitt, David J ^a   Ho, Tony W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Benzalkonium chloride; COSOPT; Dorzolamide; Glaucoma; Intraocular pressure; Ocular hypertension; Timolol

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; PRESERVATIVE;

ADULT; ANOREXIA; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EYE BURNING; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; PARALLEL DESIGN; PARANASAL SINUS DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER;

ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PRESERVATIVES, PHARMACEUTICAL; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 78549255878     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1397-7     Document Type: Article

References (23)

1. NL Burstein 1980 Corneal cytoxicity of topically applied drugs, vehicles, and preservatives Surv Ophthalmol 25 1 15 30 1:CAS:528:DyaL3cXlsVant7o%3D 10.1016/0039-6257(80)90072-7 6998034
2. C Baudouin 2008 Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma Acta Ophthalmol 86 7 716 726 10.1111/j.1755-3768.2008.01250.x 18537937
3. IP Kaur S Lal C Rana S Kakkar H Singh 2009 Ocular preservatives: associated risks and newer options Cutan Ocul Toxicol. 28 3 93 103 1:CAS:528:DC%2BD1MXhtVamtb3I 10.1080/15569520902995834 19505226
4. DC Broadway I Grierson C O'Brien RA Hitchings 1994 Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile Arch Ophthalmol 112 11 1437 1445 1:STN:280:DyaK2M%2FntV2nsA%3D%3D 7980133 (Pubitemid 24350506)
5. EW Leung FA Medeiros RN Weinreb 2008 Prevalence of ocular surface disease in glaucoma patients J Glaucoma. 17 5 350 355 10.1097/IJG.0b013e31815c5f4f 18703943
6. R Zabel G Mintsioulis I MacDonald J Valberg S Tuft 1989 Corneal toxic changes after cataract extraction Can J Ophthalmol 24 7 311 316 1:STN:280:DyaK3c7mslGntQ%3D%3D 2624912
7. D Ormrod K McClellan 2000 Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma Drugs & Aging 17 477 496 1:CAS:528:DC%2BD3MXnvFSgsg%3D%3D 10.2165/00002512-200017060-00005
8. JE Frampton CM Perry 2006 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension Drugs Aging. 23 12 977 995 1:CAS:528:DC%2BD2sXhsFynsrw%3D 10.2165/00002512-200623120-00005 17154662 (Pubitemid 44940746)
9. Merck & Co., Inc. (2005) COSOPT® (dorzolamide hydrochloride-timolol maleate ophthalmic solution) sterile ophthalmic solution. Prescribing information. Available at: http://www.merck.com/product/usa/pi- circulars/
10. JE Boyle K Ghosh DK Gieser IA Adamsons 1998 A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group Ophthalmology 105 10 1945 1951 1:STN:280:DyaK1M%2FgtlKgtA%3D%3D 10.1016/S0161-6420(98)91046-6 9787368 (Pubitemid 28509738)
11. CM Clineschmidt RD Williams E Snyder IA Adamsons 1998 A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group Ophthalmology 105 10 1952 1959 1:STN:280:DyaK1M%2FgtlKgtQ%3D%3D 10.1016/S0161-6420(98)91047-8 9787369 (Pubitemid 28509739)
12. J Hutzelmann S Owens A Shedden I Adamsons E Vargas 1998 Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group Br J Ophthalmol. 82 11 1249 1253 1:STN:280:DyaK1M7itlCjsA%3D%3D 10.1136/bjo.82.11.1249 9924327
13. K Strohmaier E Snyder H DuBiner I Adamsons 1998 The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group Ophthalmology 105 10 1936 1944 1:STN:280:DyaK1M%2FgtlKgtw%3D%3D 10.1016/S0161-6420(98)91045-4 9787367 (Pubitemid 28509737)
14. RD Fechtner PJ Airaksinen AJ Getson CR Lines IA Adamsons COSOPT versus XALATAN Study Groups 2004 Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials Acta Ophthalmol Scand 82 1 42 48 1:CAS:528:DC%2BD2cXitVyrs70%3D 10.1046/j.1600-0420.2004.0205.x 14982045 (Pubitemid 38228661)
15. Merck, Sharp and Dohme Limited (2009) Cosopt preservative-free single dose eye drops. Summary of product characteristics. Available at: http://emc.medicines.org.uk/medicine/19142/SPC/Cosopt+Preservative-Free, +Single+Dose+Eye+Drops/
16. Merck Frosst (2009) COSOPT (dorzolamide hydrochloride and timolol maleate). Product monograph. Available at: http://www.merckfrosst.ca/assets/en/ pdf/products/COSOPT-0902-a-126262-E.pdf
17. Laibovitz R, Zimmerman K, Getson A, Shedden A, Laurence J, Adamsons I (1999) Comparison of the efficacy and tolerability of preservative free 2.0% dorzolamide/0.5% timolol (PF dorz/tim) and 2.0% dorzolamide/0.5% timolol (dorz/tim). Invest Ophthal Vis Sci 40:S665 Abstract 3510-B368
18. P Ashton SK Podder VH Lee 1991 Formulation influence on conjunctival penetration of four beta blockers in the pigmented rabbit: a comparison with corneal penetration Pharm Res 8 9 1166 1174 1:CAS:528:DyaK3MXlvV2ls74%3D 10.1023/A:1015810619869 1788163
19. P Van der Bijl AD van Eyk D Meyer 2001 Effects of three penetration enhancers on transcorneal permeation of cyclosporine Cornea 20 5 505 508 10.1097/00003226-200107000-00013 11413407 (Pubitemid 32565790)
20. P Pellinen J Lokkila 2009 Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost Ophthalmic Res 41 2 118 122 10.1159/000192082 19147999
21. C Erb U Gast D Schremmer 2008 German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye Graefes Arch Clin Exp Ophthalmol 246 11 1593 1601 10.1007/s00417-008-0881-9 18648841
22. PJ Pisella P Pouliquen C Baudouin 2002 Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medications Br J Ophthalmol 86 418 423 1:STN:280:DC%2BD383is1alsw%3D%3D 10.1136/bjo.86.4.418 11914211 (Pubitemid 34293291)
23. N Jaenen C Baudouin P Pouliquen G Manni A Figueiredo T Zeyen 2007 Ocular symptoms and signs with preserved and preservative-free glaucoma medications Eur J Ophthalmol. 17 3 341 349 1:STN:280:DC%2BD2szitlSmsQ%3D%3D 17534814